ME - 23andMe Inc. Company Long-Term Debts

Graphic logo of 23andMe Holding Co (ME)

The business of 23andMe Holding Co. (ME) is in a deep managerial deadlock due to a conflict between top management and the board of directors, which calls the transparency of processes into question. Revenue is generated through the sale of genetic tests and by providing pharma giants with access to data arrays. This price chart, which serves as confirmation of the market valuation, reflects a debt load at the level of 0.04. The foundation of its stability is a colossal archive of biodata, which creates a powerful defensive barrier against competitors.

ME (23andMe Inc.) Company Long-Term Liabilities history from 07/04/2022 to 04/05/2025

23andMe Inc. (ME) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price 23andme.com|ME - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization 23andMe|ME - Total Company Value
- book value of equity indicators:
Net Assets per Single Share 23andMe|ME - Company Net Assets|Market-to-Book Ratio 23andme.com|ME - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient 23andMe Holding Co.|ME - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient 23andMe Inc|ME - Company Debts|Debts to Net Assets 23andMe|ME - Company Long-Term Debt|Company Current Liabilities 23andMe|Quick Ratio 23andme.com
- net income and valuation multiples indicators:
ME - Company Net Income
Analysis of all company metrics:ME 23andme.com
Signature product of 23andMe Holding Co.

Long-term debt reflects the market value of 23andMe Holding Co. (ME) obligations with maturities exceeding one year. By analyzing this long-term debt chart, an investor can determine the volume of external financing allocated for strategic development. This metric measures the stability of the liability structure within a fundamental valuation. For a company with a high cash burn rate in biotechnology, this indicator is critical. Rising debt amid depleting liquidity signals increased insolvency risks.

Competitors of 23andMe Holding Co. (ME)

A: Company Long-Term Indebtedness|Quest Diagnostics Incorporated - Company Long-Term Debts|ILMN - Company Long-Term Debts|Cologuard (EXAS) - Company Long-Term Debt|RVTY (Revvity Corp) - Company Long-Term Debt|Company Long-Term Liabilities BIO|Long-Term Debt anbio.com NNNN|Company Long-Term Debt Sotera Health (SHC)|Long-Term Debt Volume Quidel Corporation|Company Long-Term Debts OPK (OPKO Corp)|Long-Term Debt Volume CareDx (CDNA)|MRVI - Company Long-Term Debt|Long-Term Debt Volume fulgentgenetics.com FLGT|Standard BioTools (LAB) - Company Long-Term Debt|Company Long-Term Liabilities Cytek Biosciences Inc|OSUR (OraSure Technologies Inc) - Company Long-Term Debts|Company Long-Term Debts Exagen Diagnostics|Company Long-Term Debt MDxHealth SA (MDXH)|luciddx.com - Company Long-Term Indebtedness|Company Long-Term Debts PRE (Prenetics)|IMDX: Company Long-Term Indebtedness|TRIB - Company Long-Term Debt|ProPhase Labs Corp (PRPH) - Company Long-Term Liabilities|AIMD: Company Long-Term Debts|Long-Term Debt codiagnostics.com (CODX)|Company Long-Term Liabilities HSCS|BMRA: Company Long-Term Loans and Borrowings|Company Long-Term Debts CDIO|VRAX (Virax Biolabs Corp) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Bluejay Diagnostics BJDX|aspirawh.com (AWH) - Long-Term Debt|AXDX - Company Long-Term Debt|CNTG: Company Long-Term Debt|ENZ: Company Long-Term Debts|Company Long-Term Indebtedness FRES|GENE (Genetic Technologies Ltd) - Company Long-Term Debts|psychemedics.com (PMD) - Long-Term Debt Volume